Overview

Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study

Status:
Not yet recruiting
Trial end date:
2027-09-01
Target enrollment:
Participant gender:
Summary
This is a prospective, multi-center, real-world study designed to evaluate the efficacy and safety of albumin-bound paclitaxel versus paclitaxel or docetaxel in adjuvant treatment of breast cancer.
Phase:
N/A
Details
Lead Sponsor:
Chinese Academy of Medical Sciences
Collaborator:
CSPC Ouyi Pharmaceutical Co., Ltd.
Treatments:
Albumin-Bound Paclitaxel
Cyclophosphamide
Docetaxel
Doxorubicin
Epirubicin
Paclitaxel
Pirarubicin